Description: This 42D2 monoclonal antibody reacts with mouse CD370, which is also known as DNGR-1 or Clec9A. CD370 is a C-type lectin-like receptor expressed on conventional and plasmacytoid dendritic cells (DCs). In particular, CD8+ conventional DCs in the thymus, spleen, and lymph nodes, as well as CD24+ DCs in the blood, express CD370. This receptor is not detectable on most B cells, T and NK cells, monocytes, and macrophages. The cytoplasmic domain of CD370 contains an ITAM motif that has been demonstrated to phosphorylate Syk tyrosine kinase, leading to NFAT activation. This signaling reportedly mediates the presentation of necrotic cell-associated antigens by CD8+ DCs in innate immunity. Applications Reported: This 42D2 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 42D2 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.CLEC9A is a group V CTLR (C-type lectin-like receptor) that functions as an activation receptor and is expressed on myeloid lineage cells. This protein is also expressed at the cell surface and acts as glycosylated dimers which mediate endocytosis, but not phagocytosis (Poulin LF et al, 2010). It facilitates antigen uptake and presentation, and may provide a suitable target for antibody-mediated antigen delivery. CLEC9A is important for conveying information from necrotic cells to T-cells and defines a pathway by which adaptive immune responses can be initiated in the absence of infection. It recruits Syk to mediate sensing of necrosis by the principal DC subset involved in regulating cross priming to cell-associated antigens. Signaling via this kinase occurs through a novel pathway involving CARD9 which induce a variety of cellular responses including the induction of cytokines (such as TNF, IL-6, IL-10, IL-23, and IL-2), the respiratory burst, and the production of Arachidonic acid. In addition, it also induces TH17 (T-helper type 17) adaptive responses in vivo. Expression of CLEC9A is highly restricted in peripheral blood, being detected only on BDCA3+ DCs and on a small subset of CD14+ CD16- monocytes. CLEC9A serves as a new marker to distinguish subtypes of DCs.
|4° C, store in dark, DO NOT FREEZE!|
|PBS with 0.1% gelatin and 0.09% sodium azide; pH 7.2|
For Research Use Only.
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok